Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Leuk Lymphoma. 2017 Dec 18;59(9):2188–2200. doi: 10.1080/10428194.2017.1410882

Figure 2. NMR STD and FRET data for Runt domain inhibitors.

Figure 2

A. Results of NMR saturation transfer (STD) analysis for AI-7–54. The structure of AI-7–54 is shown with a 1D 1H NMR spectrum of the compound below. Arrows indicate resonance assignments. The middle spectrum shows 1D difference spectrum for Cerulean-Runt domain + AI-7–54. Bottom spectrum shows 1D difference spectrum for Venus-CBFβ, demonstrating a lack of binding.

B. Results of STD analysis for AI-8–45, as in panel A.

C,D. Results of FRET analysis for the initial lead AI-7–54 (C) and optimized compounds AI-8–45 and AI-9–54 (D). Calculated IC50 values (average of two measurements ± standard deviation) are shown.